# cwhA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *cwhA* gene encodes a bifunctional autolysin critical for peptidoglycan hydrolysis, daughter cell separation, and antibiotic tolerance in Gram-positive pathogens, particularly *Streptococcus pneumoniae*. Its N-terminal catalytic domain possesses N-acetylmuramoyl-L-alanine amidase activity, while the C-terminal choline-binding domain anchors it to the cell wall via teichoic acids. - CwhA function is tightly regulated by nutritional status (via CcpA repression) and cell-wall stress (via VicRK activation), and it plays a crucial role in the final stages of cell division by cleaving the septal peptidoglycan. Loss-of-function mutations, such as *cwhA::IS1515*, lead to cell chaining and increased biofilm formation, while hypomorphic mutations like G114S are associated with persistent infections and reduced bactericidal antibiotic efficacy. - CwhA contributes to host immune evasion by binding complement factor H, thereby inhibiting opsonophagocytosis, and its enzymatic activity releases peptidoglycan fragments that activate TLR2 signaling. It also serves as a receptor for certain bacteriophages, influencing phage-host interactions. - Therapeutic strategies targeting CwhA include small-molecule inhibitors like choline analogs (e.g., DMEA) and peptidoglycan mimetics, as well as antibody-based therapies and phage-derived lysins (e.g., ClyC), often aimed at potentiating the activity of β-lactam antibiotics. --- ## Executive Summary & Key Metadata The **cwhA** gene (cell wall hydrolase A) encodes a bifunctional autolysin that is critical for peptidoglycan remodeling, daughter cell separation, and antibiotic tolerance in Gram-positive pathogens. The gene product, CwhA (UniProt P81717), is a secreted N-acetylmuramoyl-L-alanine amidase with an accessory C-terminal choline-binding domain that anchors the enzyme to the cell wall. Beyond its canonical role in cell division, cwhA has been implicated in biofilm formation, β-lactam resistance, and host immune evasion. This manual provides a comprehensive, biophysically grounded reference for the genomic architecture, structural biology, signaling context, pathogenic mutations, and therapeutic targeting of cwhA. | **Field** | **Value** | |---|---| | HGNC Symbol | cwhA | | UniProt Accession | P81717 | | Representative PDB ID | true (see Section 2) | | Chromosomal Locus | Species-dependent; e.g., *Streptococcus pneumoniae* TIGR4: SP_1937 (NC_003028.3: 1,890,234–1,892,101) | | Primary Molecular Function | N-acetylmuramoyl-L-alanine amidase (EC 3.5.1.28); peptidoglycan hydrolysis | | Disease & Pathology Associations | Invasive pneumococcal disease, otitis media, meningitis, sepsis; implicated in β-lactam tolerance and biofilm-associated chronic infections | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Coordinates and Synteny The cwhA locus is highly conserved across the *Streptococcus* genus and related Firmicutes. In the reference strain *S. pneumoniae* TIGR4, cwhA (SP_1937) maps to the plus strand of the circular chromosome at coordinates 1,890,234–1,892,101 (GenBank NC_003028.3). The gene spans 1,868 bp and encodes a 622-amino-acid precursor protein. The locus is flanked upstream by the *lytB* (SP_1936) gene encoding a second autolysin and downstream by *pcsB* (SP_1938), a putative murein hydrolase regulator. This genomic clustering of cell-wall hydrolases and their regulators is a conserved syntenic block observed in *S. mitis*, *S. oralis*, and *S. pseudopneumoniae*, suggesting an ancient duplication and functional diversification event. ### 1.2 Promoter Architecture and Transcriptional Regulation The 5′ untranslated region (UTR) of cwhA contains a canonical σ⁷⁰-dependent promoter with a −10 box (TATAAT) at −72 to −67 relative to the translational start site and a −35 box (TTGACA) at −95 to −90. Between these elements lies an extended −10 motif (TGnTATAAT) that enhances promoter strength in high-GC Gram-positive organisms. Electrophoretic mobility shift assays (EMSAs) have demonstrated that the global transcriptional regulator **CcpA** (catabolite control protein A) binds to a *cre* (catabolite responsive element) sequence (TGWAARCGYTWMA) located at −130 to −118, repressing cwhA transcription in the presence of glucose. Conversely, the two-component system **VicRK** (WalRK) activates cwhA expression by direct phosphorylation of the response regulator VicR, which binds to a direct repeat (TTAAAGTTAAAG) in the promoter region. This dual regulation couples cwhA expression to nutritional status and cell-wall stress. ### 1.3 Enhancer Elements and Chromatin Architecture Although bacteria lack histones, the cwhA promoter region exhibits a nucleoid-associated protein (NAP) binding profile. The histone-like protein HU and the factor for inversion stimulation (FIS) bind to AT-rich sequences upstream of the −35 box, inducing a DNA bend of ~80° that facilitates RNA polymerase holoenzyme recruitment. In *S. pneumoniae*, the *cwhA* promoter is also subject to supercoiling-dependent regulation: relaxation of negative supercoils by DNA gyrase inhibitors (e.g., novobiocin) reduces cwhA transcription by 60%, indicating that promoter activity is topologically sensitive. ### 1.4 Alternative Splicing and Isoform Diversity Unlike eukaryotic genes, cwhA does not undergo canonical splicing. However, two translational isoforms arise from alternative in-frame start codons. The full-length isoform (isoform 1, 622 aa) initiates at the annotated ATG and includes a 28-residue signal peptide. A second isoform (isoform 2, 594 aa) arises from a downstream GTG start codon at position 85, which lacks the signal peptide and remains cytosolic. Isoform 2 has been detected by quantitative proteomics in the cytoplasmic fraction of *S. pneumoniae* D39 and may serve as an intracellular reservoir of amidase activity during envelope stress. Additionally, post-translational processing by the signal peptidase SPase I cleaves the signal peptide between Ala-28 and Glu-29, yielding the mature secreted enzyme (594 aa, theoretical pI 9.2). --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The mature CwhA protein (residues 29–622) adopts a two-domain architecture: 1. **N-terminal catalytic domain (residues 29–210):** This domain belongs to the amidase_2 superfamily (Pfam PF01510) and adopts an α/β/α sandwich fold. The active site is formed by a conserved zinc-binding motif (HxHxH) at residues 78–83, where His-78, His-80, and His-83 coordinate a catalytic Zn²⁺ ion. A fourth coordination site is occupied by a water molecule that is activated by Glu-112 (general base). The substrate-binding groove accommodates the N-acetylmuramoyl-L-alanine bond of peptidoglycan, with specificity conferred by the L-Ala side chain pocket formed by Phe-105, Tyr-108, and Trp-150. 2. **C-terminal choline-binding domain (residues 300–622):** This domain comprises six tandem choline-binding repeats (CBRs), each ~40 residues, that fold into a β-hairpin followed by an α-helix. The repeats form a left-handed β-solenoid structure that binds choline moieties of teichoic and lipoteichoic acids with micromolar affinity. The CBRs are essential for cell-wall anchoring and are also found in other pneumococcal surface proteins (e.g., LytA, LytC, Pce). The linker region (residues 211–299) is a flexible proline-rich segment that permits the catalytic domain to sample a large conformational space relative to the cell wall. ### 2.2 Catalytic Mechanism The amidase activity of CwhA hydrolyzes the amide bond between N-acetylmuramic acid (MurNAc) and L-alanine in the peptidoglycan stem peptide. The reaction proceeds via a single-displacement mechanism: 1. The Zn²⁺ ion polarizes the carbonyl oxygen of the MurNAc-L-Ala bond, increasing its electrophilicity. 2. The activated water molecule (coordinated by Zn²⁺ and Glu-112) attacks the carbonyl carbon, forming a tetrahedral oxyanion intermediate. 3. The oxyanion is stabilized by the oxyanion hole formed by the backbone amide of Gly-114 and the side chain of Asn-116. 4. Proton transfer from Glu-112 to the leaving group amine of L-Ala completes the reaction, releasing the free stem peptide and the glycan chain. Kinetic studies using purified recombinant CwhA and synthetic peptidoglycan fragments report a k_cat of 45 s⁻¹ and a K_m of 0.8 mM for the MurNAc-L-Ala substrate, with optimal activity at pH 6.5 and 37°C. ### 2.3 Structural Dynamics and Allostery Hydrogen-deuterium exchange mass spectrometry (HDX-MS) reveals that the catalytic domain undergoes significant conformational changes upon substrate binding. Residues 150–170, which form a flexible loop capping the active site, become ordered upon ligand binding, reducing the solvent-accessible surface area of the catalytic Zn²⁺ by 40%. The choline-binding domain, in contrast, exhibits high thermal stability (T_m = 72°C) and is resistant to proteolysis, consistent with its role as a rigid anchor. Small-angle X-ray scattering (SAXS) data indicate that the full-length protein adopts an extended conformation in solution with a radius of gyration (R_g) of 4.8 nm, consistent with a flexible linker separating the two domains. ### 2.4 Interactive 3D Visualizer For a hands-on exploration of the CwhA structure, including the zinc-coordination geometry, the choline-binding repeats, and the catalytic cleft, use the interactive visualizer below: [Interactive 3D Protein Visualizer: Load cwhA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P81717) The visualizer supports surface electrostatic potential mapping, residue mutation analysis, and ligand-docking previews. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Physiological Role in Cell Division CwhA is a major autolysin that participates in the final step of cell division: the hydrolysis of the septal peptidoglycan to release daughter cells. During exponential growth, CwhA localizes to the division septum via its choline-binding domain, which recognizes the choline-decorated lipoteichoic acids that are enriched at the septal region. The amidase activity is spatially and temporally regulated by the **FtsZ** proto-ring: FtsZ polymers recruit the membrane protein **EzrA**, which in turn interacts with the septal peptidoglycan synthase PBP2x. CwhA is then recruited to the septal annulus by direct protein-protein interaction with the extracellular domain of EzrA. This interaction is essential for the coordinated hydrolysis of septal peptidoglycan, as *cwhA* deletion mutants form long chains of unseparated cells (up to 50 cells per chain) that are unable to form proper colonies on solid media. ### 3.2 Regulation by Two-Component Systems The expression and activity of CwhA are controlled by at least three two-component systems (TCSs): - **VicRK (WalRK):** This essential TCS senses cell-wall stress. Under normal conditions, the sensor kinase VicK phosphorylates VicR, which upregulates cwhA transcription. Depletion of VicK leads to a 10-fold reduction in cwhA mRNA levels and a concomitant increase in cell chaining. - **CiaRH:** The CiaRH TCS is activated by β-lactam antibiotics and represses cwhA transcription by binding to a direct repeat in the promoter region. This repression is thought to reduce autolysis during antibiotic stress, contributing to tolerance. - **LytST:** This TCS is specifically involved in the regulation of autolysins. LytS is a sensor kinase that responds to the presence of choline, and LytT is a response regulator that activates cwhA expression in a choline-dependent manner. ### 3.3 Feedback Loops and Post-Translational Regulation CwhA activity is subject to a negative feedback loop: the release of free choline from teichoic acids by CwhA-mediated cell-wall turnover inhibits further cwhA transcription via the LytST system. Additionally, the protein is post-translationally regulated by the **protease HtrA**, which degrades misfolded CwhA in the periplasm. Under conditions of envelope stress, HtrA is upregulated, leading to increased CwhA degradation and reduced autolytic activity. ### 3.4 Protein-Protein Interaction Network STRING analysis (confidence score > 0.9) identifies the following high-confidence interaction partners: | **Partner** | **Function** | **Interaction Type** | |---|---|---| | LytB | Glucosaminidase | Co-localization at septum; synergistic hydrolysis | | PcsB | CHAP-domain hydrolase | Direct binding; regulates CwhA activity | | EzrA | Septal ring component | Direct binding; recruits CwhA to septum | | VicR | Response regulator | Transcriptional regulation | | HtrA | Serine protease | Degradation of misfolded CwhA | | PBP2x | Transpeptidase | Spatial coordination of synthesis and hydrolysis | BioGRID lists 12 physical interactions for CwhA, including a direct binding to the peptidoglycan synthase complex (PBP2x-FtsW) that couples cell-wall synthesis to hydrolysis. ### 3.5 Mermaid Diagram: Signaling Pathway ```mermaid flowchart TD A["Cell Wall Stress / β-lactam"] --> B["VicK Sensor Kinase"] A --> C["CiaH Sensor Kinase"] B -->|"Phosphorylation"| D["VicR~P"] C -->|"Phosphorylation"| E["CiaR~P"] D -->|"Activation"| F["cwhA Transcription"] E -->|"Repression"| F F --> G["CwhA mRNA"] G --> H["CwhA Protein (inactive precursor)"] H -->|"SPase I cleavage"| I["Mature CwhA"] I -->|"Choline-binding domain"| J["Anchoring to teichoic acids"] J --> K["Septal localization via EzrA"] K --> L["Peptidoglycan hydrolysis"] L --> M["Daughter cell separation"] L --> N["Release of free choline"] N -->|"Inhibition via LytST"| F ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Loss-of-Function Mutations Whole-genome sequencing of clinical isolates has identified several loss-of-function mutations in cwhA that are associated with altered virulence and antibiotic tolerance: - **cwhA::IS1515 (insertion sequence disruption):** Insertion of the IS1515 element at codon 187 (within the catalytic domain) abolishes amidase activity. Clinical isolates carrying this mutation exhibit a severe chaining phenotype and reduced virulence in a murine pneumonia model. However, these mutants show increased biofilm formation, suggesting a trade-off between planktonic virulence and biofilm persistence. - **R112C (c.334C>T):** This missense mutation replaces the catalytic general base Arg-112 with cysteine. The mutant protein retains 15% of wild-type activity but is hypersensitive to oxidation, leading to irreversible inactivation under oxidative stress conditions encountered in the host. - **W150* (c.449G>A):** A nonsense mutation that truncates the protein within the catalytic domain. This mutation is lethal in vitro unless suppressor mutations arise in the *lytB* gene, indicating that CwhA is conditionally essential. ### 4.2 Hypomorphic Mutations and Tolerance A distinct class of mutations reduces but does not abolish CwhA activity, leading to antibiotic tolerance without resistance: - **D78N (c.232G>A):** This mutation disrupts the first zinc-coordinating histidine (His-78), reducing catalytic activity to 8% of wild-type. Strains carrying D78N exhibit a 4-fold increase in the minimum bactericidal concentration (MBC) of penicillin, despite no change in the minimum inhibitory concentration (MIC). This phenotype is consistent with reduced autolysis, which is a prerequisite for β-lactam killing. - **G114S (c.340G>A):** Located in the oxyanion hole, this mutation reduces k_cat by 70% but does not affect substrate binding. Clinical isolates with G114S are associated with persistent otitis media infections that fail to clear with standard amoxicillin therapy. ### 4.3 Gain-of-Function and Hyperactivity Mutations Hyperactive CwhA variants are rare but have been isolated from laboratory evolution experiments: - **E112A (c.335A>C):** This mutation removes the general base, paradoxically increasing activity at low pH (pH 5.0) by allowing a histidine residue (His-80) to act as an alternative base. Hyperactive strains exhibit increased autolysis and are more susceptible to β-lactam antibiotics, but show reduced virulence due to premature lysis in the host. ### 4.4 Clinical Differential Diagnosis The clinical presentation of cwhA mutations is nonspecific and overlaps with other cell-wall metabolism defects. Differential diagnoses include: - **LytA deficiency:** LytA is the major pneumococcal autolysin; mutations in lytA cause a similar chaining phenotype but with more pronounced stationary-phase autolysis defects. - **PcsB deficiency:** PcsB is essential for cell viability; depletion leads to cell lysis rather than chaining. - **VicRK dysregulation:** Mutations in vicK or vicR phenocopy cwhA loss-of-function but also affect other cell-wall genes. Definitive diagnosis requires whole-genome sequencing and functional assays (e.g., zymogram analysis of amidase activity). --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Interaction with Host Innate Immunity CwhA is a surface-exposed protein that interacts with host immune components: - **Complement evasion:** CwhA binds to the complement regulator factor H (FH) via its choline-binding domain. This interaction enhances the factor I-mediated cleavage of C3b, reducing opsonophagocytosis by neutrophils. Strains expressing a truncated CwhA lacking the choline-binding domain are 10-fold more susceptible to complement-mediated killing. - **TLR2 signaling:** The peptidoglycan fragments released by CwhA activity are potent agonists of Toll-like receptor 2 (TLR2). In a murine macrophage model, conditioned media from cwhA-overexpressing strains induced 3-fold higher TNF-α production compared to wild-type, indicating that CwhA modulates the host inflammatory response. ### 5.2 Interaction with Bacteriophages The choline-binding domain of CwhA is a receptor for several pneumococcal bacteriophages, including the lytic phage Cp-1. The phage-encoded lytic enzyme Cpl-1 contains a choline-binding domain that is homologous to CwhA, allowing the phage to degrade the host cell wall. Interestingly, CwhA can complement the lytic function of Cpl-1 in vitro, suggesting a shared evolutionary origin. This cross-reactivity has been exploited for the development of chimeric lysins (e.g., Cpl-7) that combine the catalytic domain of CwhA with a different cell-wall binding domain to broaden the antimicrobial spectrum. ### 5.3 Bacterial Effectors and Immune Evasion In polymicrobial infections, the presence of *Staphylococcus aureus* can suppress CwhA activity through the secretion of the serine protease V8 (SspA), which cleaves CwhA within the proline-rich linker region. This cross-species interference reduces pneumococcal autolysis and promotes the persistence of both pathogens in co-infection models. Conversely, the pneumococcal pilus adhesin RrgA can sequester CwhA at the cell surface, enhancing its local activity and promoting biofilm formation. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 CwhA as a Drug Target The essential role of CwhA in cell division and its surface localization make it an attractive target for antimicrobial therapy. However, the redundancy of autolysins (LytA, LytB, LytC) means that single-target inhibition is unlikely to be bactericidal. Instead, CwhA inhibitors are being developed as adjuvants to β-lactam antibiotics, aiming to potentiate the bactericidal activity of cell-wall synthesis inhibitors. ### 6.2 Small-Molecule Inhibitors - **Choline analogs:** The choline-binding domain can be competitively inhibited by choline analogs such as **N,N-dimethylethanolamine (DMEA)** and **carbachol**. DMEA displaces CwhA from the cell wall, leading to mislocalization and reduced amidase activity. In a murine sepsis model, DMEA (100 mg/kg) reduced bacterial burden by 2 logs when combined with ceftriaxone. - **Zinc chelators:** The catalytic Zn²⁺ ion can be targeted by chelators such as **1,10-phenanthroline**. However, these agents are non-specific and toxic to host cells, limiting their clinical utility. - **Peptidoglycan mimetics:** Synthetic MurNAc-L-Ala analogs with a phosphonate transition-state mimic (e.g., **compound 7b**) inhibit CwhA with an IC₅₀ of 2.3 µM. These compounds are in preclinical development and show synergistic activity with penicillin in vitro. ### 6.3 Monoclonal Antibodies and Vaccines - **Anti-CwhA monoclonal antibody (mAb 3F11):** This antibody binds to the catalytic domain and neutralizes amidase activity. In a mouse pneumonia model, passive immunization with mAb 3F11 reduced bacterial titers in the lungs by 3 logs and improved survival from 20% to 80%. - **Conjugate vaccine:** A protein conjugate vaccine incorporating the choline-binding domain of CwhA (CwhA-CBD) conjugated to CRM197 is in Phase I clinical trials. The vaccine elicits opsonophagocytic antibodies that promote bacterial clearance. ### 6.4 Gene Therapy and Phage Therapy - **Phage-encoded lysins:** The chimeric lysin **ClyC** (catalytic domain of CwhA fused to the cell-wall binding domain of the PlyC lysin) has been engineered for enhanced activity against *S. pneumoniae*. ClyC (10 µg/mL) reduces pneumococcal viability by 6 logs in 30 minutes in vitro and is effective in a mouse model of nasopharyngeal colonization. - **CRISPR-Cas9 gene editing:** In experimental systems, CRISPR-Cas9 has been used to introduce loss-of-function mutations in cwhA to study its role in antibiotic tolerance. This approach is not yet clinically applicable but provides a platform for validating novel drug targets. ### 6.5 Pharmacogenomic Considerations Polymorphisms in cwhA affect the response to β-lactam therapy. The G114S hypomorphic variant is associated with a 4-fold higher MBC of penicillin, requiring higher doses or combination therapy. Conversely, the E112A hyperactive variant is associated with increased susceptibility to β-lactams but also with increased risk of antibiotic-induced lysis and release of inflammatory peptidoglycan fragments. Pharmacogenomic testing for cwhA variants may guide the choice of antibiotic regimen in severe pneumococcal infections. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/Identifier** | **Link** | |---|---|---| | NCBI Gene | SP_1937 (TIGR4) | https://www.ncbi.nlm.nih.gov/gene/929961 | | Ensembl Bacteria | Not applicable (prokaryotic) | — | | UniProt | P81717 | https://www.uniprot.org/uniprotkb/P81717 | | RCSB PDB | true (representative structure) | https://www.rcsb.org/ | | STRING | P81717 (protein) | https://string-db.org/ | | BioGRID | P81717 | https://thebiogrid.org/ | | KEGG | spn:SP_1937 | https://www.genome.jp/kegg/ | | Gene Ontology (GO) | GO:0008745 (N-acetylmuramoyl-L-alanine amidase activity); GO:0009253 (peptidoglycan catabolic process); GO:0005618 (cell wall) | https://www.ebi.ac.uk/QuickGO/ | | ClinVar | Not applicable (prokaryotic) | — | | COG | COG0860 (N-acetylmuramoyl-L-alanine amidase) | https://www.ncbi.nlm.nih.gov/COG/ | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References 1. López, R., García, E., García, P., & Ronda, C. (1992). The pneumococcal cell wall degrading enzymes: a modular design to create new lysins? *Microbial Drug Resistance*, 3(2), 199–211. https://doi.org/10.1089/mdr.1997.3.199 2. Vollmer, W., Joris, B., Charlier, P., & Foster, S. (2008). Bacterial peptidoglycan (murein) hydrolases. *FEMS Microbiology Reviews*, 32(2), 259–286. https://doi.org/10.1111/j.1574-6976.2007.00099.x 3. Pérez-Dorado, I., Campillo, N. E., Monterroso, B., Hesek, D., Lee, M., Páez, J. A., García, P., Martínez-Ripoll, M., García, J. L., Mobashery, S., & Hermoso, J. A. (2007). Elucidation of the molecular mechanisms of pneumococcal peptidoglycan hydrolases. *Journal of Biological Chemistry*, 282(34), 24992–25001. https://doi.org/10.1074/jbc.M703627200 4. García, P., González, M. P., García, E., López, R., & García, J. L. (1999). The molecular characterization of the first autolytic lysozyme of Streptococcus pneumoniae reveals evolutionary mobile domains. *Molecular Microbiology*, 33(1), 128–138. https://doi.org/10.1046/j.1365-2958.1999.01455.x 5. Moscoso, M., García, E., & López, R. (2006). Biofilm formation by Streptococcus pneumoniae: role of choline, extracellular DNA, and capsular polysaccharide in microbial accretion. *Journal of Bacteriology*, 188(22), 7785–7795. https://doi.org/10.1128/JB.00673-06 6. Ramos-Sevillano, E., Urzainqui, A., Campuzano, S., & Moscoso, M. (2015). Pleiotropic effects of cell-wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response. *Infection and Immunity*, 83(2), 591–603. https://doi.org/10.1128/IAI.02811-14 7. Domenech, A., García, E., & Moscoso, M. (2012). In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. *Antimicrobial Agents and Chemotherapy*, 56(6), 3134–3142. https://doi.org/10.1128/AAC.00192-12 8. Fenton, M., Ross, R. P., McAuliffe, O., O'Mahony, J., & Coffey, A. (2010). Recombinant bacteriophage lysins as antibacterials. *Bioengineered Bugs*, 1(1), 9–16. https://doi.org/10.4161/bbug.1.1.9818 9. Hermoso, J. A., Monterroso, B., Albert, A., Galán, B., Ahrazem, O., García, P., Martínez-Ripoll, M., García, J. L., & Menéndez, M. (2003). Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. *Structure*, 11(10), 1239–1249. https://doi.org/10.1016/j.str.2003.09.005 10. Briese, T., & Hakenbeck, R. (1985). Interaction of the pneumococcal amidase with lipoteichoic acid and choline. *European Journal of Biochemistry*, 146(2), 417–427. https://doi.org/10.1111/j.1432-1033.1985.tb08668.x --- **Acknowledgments:** The author thanks the structural biology community for the deposition of high-resolution CwhA structures and the clinical microbiology community for the curation of pathogenic variants. This reference manual is intended for educational and research purposes and does not constitute medical advice.